Back to Agenda
Session 1: Increasing Diversity in Drug Discovery and Early Development
Session Chair(s)
Nicole Richie, PhD
Global Head Health Equity and Population Science, Clinical Development
Genentech, United States
Understanding that different demographics contribute to an individual’s susceptibility to disease, is an important factor in determining how people respond to medicinal products. Although omics is now widely utilized as a tool to inform and accelerate both an understanding of disease process, medicinal response, and the identification of new therapeutic targets, most data from diverse populations is lacking, leading to challenges in determining the full spectrum of variation that contributes to disease or drug response. This session will identify and discuss current strategies to include more diversity in early drug development to advance discovery work.
Learning Objective : At the conclusion of this session, participants should be able to:
- Articulate three examples demonstrating the clinical and scientific importance of diversity in genomics for discovery science and early clinical development
- List two ways genomic databases and inputs can be enriched
- Recognize how genomics can inform decision making in the drug discovery process
Speaker(s)
Speaker
Latha Palaniappan, MD, MS
Stanford School of Medicine, United States
Professor
Speaker
Mark McCarthy, MD, MA, FRCP
Genentech, United States
Executive Director, Human Genetics; Staff Scientist
Speaker
Lucia Hindorff
National Human Genome Research Institute (NHGRI), United States
Program Director
Have an account?